Summary
BeOne Medicines Ltd. (ONC) filed an Annual Report Amendment (10-K/A) on January 8, 2025, for the period ending December 31, 2023. This filing primarily pertains to the exhibits and financial statement schedules, specifically including the parent company's financial statements (Schedule I) for the years 2023, 2022, and 2021. Investors should note that this is an amendment, suggesting potential updates or clarifications to previously filed information, and a thorough review of the referenced exhibits and schedules is crucial for a comprehensive understanding of the company's financial position and performance. The limited information provided in the excerpt focuses on the documentation filed rather than detailed operational or financial performance metrics. Further details would be found within the full financial statements and exhibits referenced in Item 15 of the filing. Investors should exercise due diligence to access and analyze the complete report, including the detailed financial statements for the specified years, to ascertain any material changes or insights.
Financial Highlights
53 data points| Revenue | $2.46B |
| Gross Profit | $2.08B |
| R&D Expenses | $1.78B |
| SG&A Expenses | $1.51B |
| Operating Expenses | $3.29B |
| Operating Income | -$1.21B |
| Interest Expense | $20.80M |
| Net Income | -$881.71M |
| EPS (Basic) | $-0.65 |
| EPS (Diluted) | $-0.65 |
| Shares Outstanding (Basic) | 1.36B |
| Shares Outstanding (Diluted) | 1.36B |
Key Highlights
- 1Filing is an Annual Report Amendment (10-K/A) for BeOne Medicines Ltd. (ONC) as of December 31, 2023, filed January 8, 2025.
- 2The amendment primarily concerns Item 15: Exhibits and Financial Statement Schedules.
- 3Includes Financial Statement Schedule I for the parent company, covering fiscal years 2023, 2022, and 2021.
- 4Investors should review the referenced exhibits and detailed financial statements for a complete understanding.
- 5This filing may contain updates or clarifications to previously submitted financial information.
- 6The excerpt does not provide specific operational or detailed financial performance data, necessitating a review of the full filing.
- 7Focus is on the reporting of financial statements and exhibits, not on new business developments or strategic shifts.